- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00275977
Treatment of Myocardial Infarction With Bone Marrow Derived Stem Cells
Treatment of Myocardial Infarction With Autologous Bone Marrow Derived Stem Cells
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary coronary intervention within a few hours of a myocardial infarction has greatly reduced mortality as well as the risk of developing chronic heart failure. There are though still a large number of patients that develop symptoms of heart failure in the form of fatigue and breathlessness with physical exertion in spite of medical treatment. With the advance in stem cell technology there is now hope for the possibility of regenerating/repairing dead myocardial tissue, hence improving cardiac function.
The current study is a pilot study that is going to precede a later double blinded randomized study. The aim of the study is to evaluate patient safety, optimize procedures, and to be used in power calculation in the design of the following study.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Odense, Denmark, 5000
- Recruiting
- Department of endocrinology M, Odense University Hospital
-
Sub-Investigator:
- Malthe AM Kristiansen, MD
-
Principal Investigator:
- Moustapha Kassem, MD, Ph.D
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Chestpain
- Troponin T, > 0,1ng/ml
- Succesfull revascularization of culprit lesion with PCI.
- No more than stenosis of 2 major epicardiel coronary arteries.
Exclusion Criteria:
- Cardiogenic shock
- Known LVEF<45%
- Cardiomyopathy
- Atrialfibrillation or fluctuation
- Takyarytmia
- Infection
- Chronic inflammatory disease
Study Plan
How is the study designed?
Design Details
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Safety
|
Secondary Outcome Measures
Outcome Measure |
|---|
|
Change in left ventricular funtion at 4 months followup using contrast enhanced echocardiography
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Moustapha Kassem, MD, Ph.D, Department of endocrinology M, Odense University Hospital
Publications and helpful links
General Publications
- Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, Fichtner S, Korte T, Hornig B, Messinger D, Arseniev L, Hertenstein B, Ganser A, Drexler H. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004 Jul 10-16;364(9429):141-8. doi: 10.1016/S0140-6736(04)16626-9.
- Schachinger V, Assmus B, Britten MB, Honold J, Lehmann R, Teupe C, Abolmaali ND, Vogl TJ, Hofmann WK, Martin H, Dimmeler S, Zeiher AM. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol. 2004 Oct 19;44(8):1690-9. doi: 10.1016/j.jacc.2004.08.014.
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 020
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.